Initiated the Company's third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors Started first backfill cohorts in the ongoing Phase 1b NECTINIUM-…
● Zacks Investment ResearchNov 11, 2026 · 17:21 ET
Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?
The mean of analysts' price targets for Aktis (AKTS) points to a 105.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings …
Aktis Oncology: Padcev Is Building The Market It Wants
Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. AKTS has a cash runway into 2029, supported by $517.3M in cash and a $1.2B+ partnership with Eli …
● GlobeNewsWireOct 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors Enrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-251…
Article counts from the last market-wide feed page, across every symbol we track and not just AKTS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.